摘要
目的:系统评价参麦注射液治疗扩张型心肌病的临床疗效及安全性,为临床治疗与合理用药提供循证医学依据。方法:计算机检索中国期刊全文数据库、万方数据库、中文科技期刊全文数据库、Pub Med和Cochrane Library等数据库,全面搜集参麦注射液治疗扩张型心肌病的随机对照试验,采用Cochrane风险评价表评价其研究质量,提取资料并采用Rev Man 5.3软件进行文献荟萃(Meta)分析。结果:共纳入10个随机对照试验,累计受试者806例。Meta分析结果显示,在西医常规用药基础上联合应用参麦注射液治疗扩张型心肌病,可显著提高总有效率(RR=1.21,95%CI=1.13~1.29,Z=5.76,P<0.000 01);参麦注射液还可提高患者左心室射血分数(MD=6.15,95%CI=3.91~8.38,Z=5.40,P<0.000 01)、改善心输出量(MD=0.86,95%CI=0.60~1.12,P<0.000 01)等,且未见严重不良反应。结论:参麦注射液对扩张型心肌病确有较好的治疗作用,可提高临床总有效率,并可改善心脏指标。但由于纳入研究质量一般,尚需更多高质量的研究予以证实。
OBJECTIVE： To systematically evaluate the clinical efficacy and safety of Shenmai injection in treatment of dilated cardiomyopathy（ DCM）,so as to provide scientific evidence for clinical treatment and rational use of drugs. METHODS： CNKI,Wanfang database,VIP,Pub Med and Cochrane Library were retrieved by computers,RCTs of Shenmai injection in treatment of DCM were collected. The Cochrane Risk of Bias Assessment Table was used to evaluate the methodological quality of the research,and the data were extracted to conduct the Meta-analysis by Rev Man 5. 3 software. RESULTS： Totally 10 RCTs were involved,including 806 cases. According to Meta-analysis,the total effective rate（ RR = 1. 21,95% CI = 1. 13-1. 29,Z = 5. 76,P〈0. 000 01） can be significantly increased by using Shenmai injection combined with conventional treatment of western medicine in treatment of DCM. Shenmai injection could improve the left ventricular ejection fraction（ MD = 6. 15,95% CI = 3. 91-8. 38,Z = 5. 40,P〈0. 000 01）and cardiac output（ MD = 0. 86,95% CI = 0. 60-1. 12,P〈0. 000 01） without any severe adverse drug reactions.CONCLUSIONS： Shenmai injection can effectively in treatment of DCM,and can increase the clinical total effective rate and improve the cardiac indicators. However,more evidence-based studies are needed to further support the study due to the general quality of included RCTs.
出处
《中国医院用药评价与分析》
2017年第11期1448-1451,1456,共5页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
国家自然科学基金项目(No.81473547
No.81673829)
